董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark Iwicki | 男 | Director | 59 | 149.12万美元 | 未持股 | 2026-02-02 |
| Howard Rosen | 男 | Independent Director | 68 | 9.97万美元 | 未持股 | 2026-02-02 |
| Marjan Farid | 女 | Independent Director | 52 | 8.49万美元 | 未持股 | 2026-02-02 |
| David Lazar | 男 | Chair of the Board,Chief Operating Officer and President | 35 | 未披露 | 未持股 | 2026-02-02 |
| Todd Bazemore | 男 | Director | 55 | 94.96万美元 | 未持股 | 2026-02-02 |
| Avi Minkowitz | 男 | Director,Chief Executive Officer and Chief Financial Officer | -- | 未披露 | 未持股 | 2026-02-02 |
| Andrew I. Koven | 男 | Lead Independent Director | 68 | 12.65万美元 | 未持股 | 2026-02-02 |
| C. Daniel Myers | 男 | Independent Director | 72 | 9.22万美元 | 未持股 | 2026-02-02 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kim Brazzell | 女 | Chief Medical Officer and Head of Research and Development | 73 | 92.07万美元 | 未持股 | 2026-02-02 |
| David Lazar | 男 | Chair of the Board,Chief Operating Officer and President | 35 | 未披露 | 未持股 | 2026-02-02 |
| Darius Kharabi | 男 | Chief Business Officer | 47 | 未披露 | 未持股 | 2026-02-02 |
| Avi Minkowitz | 男 | Director,Chief Executive Officer and Chief Financial Officer | -- | 未披露 | 未持股 | 2026-02-02 |
董事简历
中英对照 | 中文 | 英文- Mark Iwicki
-
Mark Iwicki，自2015年9月起担任董事会主席。他曾担任Inhibikase Therapeutics， Inc.（制药公司）的首席执行官（2025年2月以来）。Iwicki先生从2015年9月到2025年2月担任首席执行官，从2017年8月到2021年12月担任总裁，从2015年4月到2015年9月担任董事会执行主席。加入公司之前，他曾担任Civitas Therapeutics， Inc. （Civitas，生物制药公司）的总裁兼首席执行官（2014年1月至2014年11月）。2012年12月至2014年1月，他担任Blend Therapeutics， Inc.（生物制药公司）的总裁兼首席执行官。加入Blend之前，Iwicki先生是Sunovion的总裁兼首席执行官。2007年10月至2012年6月，他在Sepracor Inc./Sunovion任职。加入Sepracor Inc.之前，他曾担任Novartis Pharmaceuticals Corporation（生物制药公司）的副总裁兼业务部门主管。1998年3月至2007年10月，他在诺华公司工作。在此之前，他在Astra Merck Inc.和Merck & Co., Inc.担任管理职务。除了担任Kala Bio， Inc.董事会成员外，他目前还担任Aerovate Therapeutics， Inc., Merus n.v。或Merus（公共临床阶段免疫肿瘤学公司），Akero Therapeutics, Inc., Third Harmonic Bio, Inc.和Q32 Bio Inc.的董事会成员，并曾担任immune Therapeutics， Inc.和Pulmatrix Inc.（所有上市公司）的董事会成员。他持有Ball State大学的工商管理学士学位和Loyola大学的工商管理硕士学位。
Mark Iwicki has served as a member of KALA BIO, Inc. board of directors since September 2015. Mr. Iwicki previoly served as KALA BIO, Inc. President from Augt 2017 to December 2021 and as Executive Chair of KALA BIO, Inc. board of directors from April 2015 to September 2015. Prior to joining KALA BIO, Inc., Mr. Iwicki served as President and Chief Executive Officer of Civitas Therapeutics, Inc., or Civitas, a biopharmaceutical company, from January 2014 to November 2014. Prior to Civitas, Mr. Iwicki served as President and Chief Executive Officer at Blend Therapeutics, Inc., or Blend, a biopharmaceutical company, from December 2012 to January 2014. Prior to Blend, Mr. Iwicki was President and Chief Executive Officer of Sunovion, a pharmaceutical company. Mr. Iwicki was at Sepracor Inc./Sunovion from October 2007 to June 2012. Prior to joining Sepracor Inc., Mr. Iwicki was Vice President and Biness Unit Head at Novartis Pharmaceuticals Corporation, a biopharmaceutical company. He was at Novartis from March 1998 to October 2007. Prior to that, Mr. Iwicki held management positions at Astra Merck Inc. and Merck & Co., Inc. In addition to serving on KALA BIO, Inc. board of directors, Mr. Iwicki also currently serves on the boards of Aerovate Therapeutics, Inc., Mer, Akero Therapeutics, Inc., Third Harmonic Bio, Inc. and Q32 Bio Inc. and formerly served on the board of Aimmune Therapeutics, Inc. and Pulmatrix Inc., all publicly traded companies. Mr. Iwicki holds a B.S. in Biness Administration from Ball State University and an M.B.A. from Loyola University. - Mark Iwicki，自2015年9月起担任董事会主席。他曾担任Inhibikase Therapeutics， Inc.（制药公司）的首席执行官（2025年2月以来）。Iwicki先生从2015年9月到2025年2月担任首席执行官，从2017年8月到2021年12月担任总裁，从2015年4月到2015年9月担任董事会执行主席。加入公司之前，他曾担任Civitas Therapeutics， Inc. （Civitas，生物制药公司）的总裁兼首席执行官（2014年1月至2014年11月）。2012年12月至2014年1月，他担任Blend Therapeutics， Inc.（生物制药公司）的总裁兼首席执行官。加入Blend之前，Iwicki先生是Sunovion的总裁兼首席执行官。2007年10月至2012年6月，他在Sepracor Inc./Sunovion任职。加入Sepracor Inc.之前，他曾担任Novartis Pharmaceuticals Corporation（生物制药公司）的副总裁兼业务部门主管。1998年3月至2007年10月，他在诺华公司工作。在此之前，他在Astra Merck Inc.和Merck & Co., Inc.担任管理职务。除了担任Kala Bio， Inc.董事会成员外，他目前还担任Aerovate Therapeutics， Inc., Merus n.v。或Merus（公共临床阶段免疫肿瘤学公司），Akero Therapeutics, Inc., Third Harmonic Bio, Inc.和Q32 Bio Inc.的董事会成员，并曾担任immune Therapeutics， Inc.和Pulmatrix Inc.（所有上市公司）的董事会成员。他持有Ball State大学的工商管理学士学位和Loyola大学的工商管理硕士学位。
- Mark Iwicki has served as a member of KALA BIO, Inc. board of directors since September 2015. Mr. Iwicki previoly served as KALA BIO, Inc. President from Augt 2017 to December 2021 and as Executive Chair of KALA BIO, Inc. board of directors from April 2015 to September 2015. Prior to joining KALA BIO, Inc., Mr. Iwicki served as President and Chief Executive Officer of Civitas Therapeutics, Inc., or Civitas, a biopharmaceutical company, from January 2014 to November 2014. Prior to Civitas, Mr. Iwicki served as President and Chief Executive Officer at Blend Therapeutics, Inc., or Blend, a biopharmaceutical company, from December 2012 to January 2014. Prior to Blend, Mr. Iwicki was President and Chief Executive Officer of Sunovion, a pharmaceutical company. Mr. Iwicki was at Sepracor Inc./Sunovion from October 2007 to June 2012. Prior to joining Sepracor Inc., Mr. Iwicki was Vice President and Biness Unit Head at Novartis Pharmaceuticals Corporation, a biopharmaceutical company. He was at Novartis from March 1998 to October 2007. Prior to that, Mr. Iwicki held management positions at Astra Merck Inc. and Merck & Co., Inc. In addition to serving on KALA BIO, Inc. board of directors, Mr. Iwicki also currently serves on the boards of Aerovate Therapeutics, Inc., Mer, Akero Therapeutics, Inc., Third Harmonic Bio, Inc. and Q32 Bio Inc. and formerly served on the board of Aimmune Therapeutics, Inc. and Pulmatrix Inc., all publicly traded companies. Mr. Iwicki holds a B.S. in Biness Administration from Ball State University and an M.B.A. from Loyola University.
- Howard Rosen
-
Howard Rosen自2014年1月以来一直担任我们的董事会成员。Rosen自2008年起担任多家生物技术行业公司顾问。他也曾担任Stanford University的化学工程讲师（2009年以来），以及管理讲师（2011年以来）。罗森先生于2016年4月至2017年3月担任上市公司AcelRxPharmaceuticals，Inc.（AcelRx）的首席执行官，并于2015年4月至2016年3月担任临时首席执行官。Rosen从2010年6月到2011年3月担任Pearl Therapeutics，Inc.临时总裁和首席执行官。从2004年到2008年，罗森先生是生物制药公司吉利德科学公司的商业策略Vice President。Rosen从2003年到2004年担任Alza Corporation（一家制药和医疗系统公司，2001年与强生公司（一家全球梦百合公司）合并）总裁。在此之前，Rosen从1994年到2003年在Alza Corporation担任多个职位。Rosen先生是AcelRx公司（一家上市公司）的董事会主席，也在Alcobra，Ltd.（一家上市公司）的董事会任职。Rosen先生目前也是私营生物技术公司Entrega，Inc.的董事会成员。Rosen先生拥有斯坦福大学（Stanford University）的化学工程学士学位，麻省理工学院（Massachusetts Institute of Technology）的化学工程硕士学位和斯坦福商学院（Stanford Graduate School of Business）的工商管理硕士学位。
Howard Rosen has served as a member of KALA BIO, Inc. board of directors since January 2014. Since 2008, Mr. Rosen has served as a consultant to several companies in the biotechnology indtry. He has served at Stanford University as an adjunct professor in Chemical Engineering since 2021 and as a lecturer in Management since 2011, and he previoly served as a lecturer in Chemical Engineering from 2009 until 2021. Mr. Rosen served as Chief Executive Officer of AcelRx Pharmaceuticals, Inc. (now Talphera, Inc.), or Talphera, a public specialty pharmaceutical company developing products for pain relief, from April 2016 to March 2017, and Interim Chief Executive Officer from April 2015 to March 2016. Mr. Rosen also served as Interim President and Chief Executive Officer of Pearl Therapeutics, Inc. from June 2010 to March 2011. From 2004 to 2008, Mr. Rosen was Vice President of Commercial Strategy at Gilead Sciences, Inc., a biopharmaceutical company. From 2003 until 2004, Mr. Rosen was President of ALZA Corporation, a pharmaceutical and medical systems company that merged in 2001 with Johnson & Johnson, a global healthcare company. Prior to that, from 1994 until 2003, Mr. Rosen held vario positions at ALZA Corporation. Mr. Rosen served on the board of directors of Talphera until February 2024 and on the board of directors of Alcobra, Ltd., a public pharmaceutical company, until November 2017. Mr. Rosen is currently a member of the board of directors of private companies, including Firecycte Therapeutics, Inc., Hammerton, Inc., and Entrega, Inc., and was a member of the board of directors of Metera Pharmaceuticals, Inc. from 2018 to 2020, Aria Pharmaceuticals, Inc. from 2020 to 2023 and Hopell Therapeutics, Inc. from 2022 to 2024. Mr. Rosen holds a B.S. in Chemical Engineering from Stanford University, an M.S. in Chemical Engineering from the Massachetts Institute of Technology and an M.B.A. from the Stanford Graduate School of Biness where he was an Arjay Miller Scholar and a Henry Ford II Scholar. - Howard Rosen自2014年1月以来一直担任我们的董事会成员。Rosen自2008年起担任多家生物技术行业公司顾问。他也曾担任Stanford University的化学工程讲师（2009年以来），以及管理讲师（2011年以来）。罗森先生于2016年4月至2017年3月担任上市公司AcelRxPharmaceuticals，Inc.（AcelRx）的首席执行官，并于2015年4月至2016年3月担任临时首席执行官。Rosen从2010年6月到2011年3月担任Pearl Therapeutics，Inc.临时总裁和首席执行官。从2004年到2008年，罗森先生是生物制药公司吉利德科学公司的商业策略Vice President。Rosen从2003年到2004年担任Alza Corporation（一家制药和医疗系统公司，2001年与强生公司（一家全球梦百合公司）合并）总裁。在此之前，Rosen从1994年到2003年在Alza Corporation担任多个职位。Rosen先生是AcelRx公司（一家上市公司）的董事会主席，也在Alcobra，Ltd.（一家上市公司）的董事会任职。Rosen先生目前也是私营生物技术公司Entrega，Inc.的董事会成员。Rosen先生拥有斯坦福大学（Stanford University）的化学工程学士学位，麻省理工学院（Massachusetts Institute of Technology）的化学工程硕士学位和斯坦福商学院（Stanford Graduate School of Business）的工商管理硕士学位。
- Howard Rosen has served as a member of KALA BIO, Inc. board of directors since January 2014. Since 2008, Mr. Rosen has served as a consultant to several companies in the biotechnology indtry. He has served at Stanford University as an adjunct professor in Chemical Engineering since 2021 and as a lecturer in Management since 2011, and he previoly served as a lecturer in Chemical Engineering from 2009 until 2021. Mr. Rosen served as Chief Executive Officer of AcelRx Pharmaceuticals, Inc. (now Talphera, Inc.), or Talphera, a public specialty pharmaceutical company developing products for pain relief, from April 2016 to March 2017, and Interim Chief Executive Officer from April 2015 to March 2016. Mr. Rosen also served as Interim President and Chief Executive Officer of Pearl Therapeutics, Inc. from June 2010 to March 2011. From 2004 to 2008, Mr. Rosen was Vice President of Commercial Strategy at Gilead Sciences, Inc., a biopharmaceutical company. From 2003 until 2004, Mr. Rosen was President of ALZA Corporation, a pharmaceutical and medical systems company that merged in 2001 with Johnson & Johnson, a global healthcare company. Prior to that, from 1994 until 2003, Mr. Rosen held vario positions at ALZA Corporation. Mr. Rosen served on the board of directors of Talphera until February 2024 and on the board of directors of Alcobra, Ltd., a public pharmaceutical company, until November 2017. Mr. Rosen is currently a member of the board of directors of private companies, including Firecycte Therapeutics, Inc., Hammerton, Inc., and Entrega, Inc., and was a member of the board of directors of Metera Pharmaceuticals, Inc. from 2018 to 2020, Aria Pharmaceuticals, Inc. from 2020 to 2023 and Hopell Therapeutics, Inc. from 2022 to 2024. Mr. Rosen holds a B.S. in Chemical Engineering from Stanford University, an M.S. in Chemical Engineering from the Massachetts Institute of Technology and an M.B.A. from the Stanford Graduate School of Biness where he was an Arjay Miller Scholar and a Henry Ford II Scholar.
- Marjan Farid
-
Marjan Farid，自2022年10月起担任Kala制药公司董事会成员。自2007年以来，法里德博士一直担任加州大学欧文分校加文·赫伯特眼科研究所的临床眼科教授、角膜、屈光和白内障外科主任和眼科副主任。她的临床实践分为病人护理、教学和研究。Farid博士的研究重点是角膜手术，特别是Kala制药公司的飞秒激光角膜移植。法里德博士也是加州大学欧文分校严重眼表疾病中心的创始人，她在那里进行角膜缘干细胞移植，以及人工角膜移植，用于治疗严重眼表疾病的患者。Farid博士还担任美国白内障和屈光外科学会角膜临床委员会主席。法里德博士在加州大学洛杉矶分校获得生物学学士学位，在加州大学圣迭戈分校获得医学博士学位。
Marjan Farid has served as a member of KALA BIO, Inc. board of directors since October 2022. Since 2007, Dr. Farid has served as Professor of Clinical Ophthalmology, Director of Cornea, Refractive & Cataract Surgery, and Vice Chair of Ophthalmic Faculty at the Gavin Herbert Eye Institute, University of California Irvine. Her clinical practice is divided beten patient care, teaching, and research. Dr. Farid's research interests foc on corneal surgery, specifically the e of the femtosecond laser for corneal transplantation. Dr. Farid is also the founder of the Severe Ocular Surface Disease Center at the University of California Irvine, where she performs limbal stem cell transplants, as ll as artificial corneal transplantation, for the treatment of patients with severe ocular surface disease. Dr. Farid also serves as the Chair of the Corneal Clinic Committee of the American Society of Cataract and Refractive Surgery. Dr. Farid received a B.S. in Biology from the University of California Los Angeles and M.D. from the University of California San Diego. - Marjan Farid，自2022年10月起担任Kala制药公司董事会成员。自2007年以来，法里德博士一直担任加州大学欧文分校加文·赫伯特眼科研究所的临床眼科教授、角膜、屈光和白内障外科主任和眼科副主任。她的临床实践分为病人护理、教学和研究。Farid博士的研究重点是角膜手术，特别是Kala制药公司的飞秒激光角膜移植。法里德博士也是加州大学欧文分校严重眼表疾病中心的创始人，她在那里进行角膜缘干细胞移植，以及人工角膜移植，用于治疗严重眼表疾病的患者。Farid博士还担任美国白内障和屈光外科学会角膜临床委员会主席。法里德博士在加州大学洛杉矶分校获得生物学学士学位，在加州大学圣迭戈分校获得医学博士学位。
- Marjan Farid has served as a member of KALA BIO, Inc. board of directors since October 2022. Since 2007, Dr. Farid has served as Professor of Clinical Ophthalmology, Director of Cornea, Refractive & Cataract Surgery, and Vice Chair of Ophthalmic Faculty at the Gavin Herbert Eye Institute, University of California Irvine. Her clinical practice is divided beten patient care, teaching, and research. Dr. Farid's research interests foc on corneal surgery, specifically the e of the femtosecond laser for corneal transplantation. Dr. Farid is also the founder of the Severe Ocular Surface Disease Center at the University of California Irvine, where she performs limbal stem cell transplants, as ll as artificial corneal transplantation, for the treatment of patients with severe ocular surface disease. Dr. Farid also serves as the Chair of the Corneal Clinic Committee of the American Society of Cataract and Refractive Surgery. Dr. Farid received a B.S. in Biology from the University of California Los Angeles and M.D. from the University of California San Diego.
- David Lazar
-
David Lazar自2025年11月起担任KALA BIO，Inc.董事会成员兼首席执行官。他于2025年8月至2025年10月担任Novabay Pharmaceuticals, Inc.（NASDAQ：NBY）的首席执行官，该公司是一家上市生物制药公司previoly，专注于开发和销售眼部护理、伤口护理和皮肤护理产品。在此之前，Lazar Previoly先生在FiEE，Inc.（前身为Minim, Inc.）（纳斯达克股票代码：FIEE）的董事会担任董事，他还在2023年12月至2025年2月期间担任首席执行官和首席财务官。Lazar先生于2025年1月2日至2025年2月26日期间担任Bio Green Med Solution Inc.（纳斯达克股票代码：BGMS）的临时首席执行官和首席财务官。Lazar先生于2022年8月至2024年4月期间担任在纳斯达克上市的Black Titan Corporation（NASDAQ：BTTC）的首席执行官，并于2022年8月至2023年10月期间担任董事和董事会主席。Lazar先生还于2024年3月至2024年8月期间担任OpGen公司（OTC：OPGN）的首席执行官兼董事会主席。Lazar先生还曾在2024年10月至2025年4月期间担任LQR Hoe Inc.（纳斯达克股票代码：YHC）的总裁和董事会成员。Lazar先生于2018年3月至2022年4月担任Activist Investing的首席执行官。
David Lazar has served as a member of KALA BIO, Inc. board of directors and Chief Executive Officer since November 2025. He served as Chief Executive Officer of Novabay Pharmaceuticals, Inc. (NASDAQ: NBY) from Augt November 2025, a public biopharmaceutical company previoly foced on the development and sale of eyecare, wound care, and skin care products, from Augt 2025 to October 2025. Prior to that, Mr. Lazar previoly served as director on the board of directors of FiEE, Inc. (formerly Minim, Inc.) (NASDAQ: FIEE) where he also previoly served as the Chief Executive Officer and Chief Financial Officer from December 2023 to February 2025. Mr. Lazar served as interim Chief Executive Officer and principal financial officer of Bio Green Med Solution Inc. (NASDAQ: BGMS), from January 2, 2025 through February 26, 2025. Mr. Lazar served as the Chief Executive Officer of Black Titan Corporation listed on Nasdaq (NASDAQ: BTTC) from Augt 2022 to April 2024, where he also served as a director and board chairman from Augt 2022 until October 2023. Mr. Lazar also served as the chief executive officer and chairman of the board of directors of OpGen, Inc. (OTC: OPGN) from March 2024 to Augt 2024. Mr. Lazar also served as the president and a member of the board of directors of LQR Hoe Inc. (NASDAQ: YHC) from October 2024 to April 2025. Mr. Lazar served as the Chief Executive Officer of Activist Investing from March 2018 to April 2022. - David Lazar自2025年11月起担任KALA BIO，Inc.董事会成员兼首席执行官。他于2025年8月至2025年10月担任Novabay Pharmaceuticals, Inc.（NASDAQ：NBY）的首席执行官，该公司是一家上市生物制药公司previoly，专注于开发和销售眼部护理、伤口护理和皮肤护理产品。在此之前，Lazar Previoly先生在FiEE，Inc.（前身为Minim, Inc.）（纳斯达克股票代码：FIEE）的董事会担任董事，他还在2023年12月至2025年2月期间担任首席执行官和首席财务官。Lazar先生于2025年1月2日至2025年2月26日期间担任Bio Green Med Solution Inc.（纳斯达克股票代码：BGMS）的临时首席执行官和首席财务官。Lazar先生于2022年8月至2024年4月期间担任在纳斯达克上市的Black Titan Corporation（NASDAQ：BTTC）的首席执行官，并于2022年8月至2023年10月期间担任董事和董事会主席。Lazar先生还于2024年3月至2024年8月期间担任OpGen公司（OTC：OPGN）的首席执行官兼董事会主席。Lazar先生还曾在2024年10月至2025年4月期间担任LQR Hoe Inc.（纳斯达克股票代码：YHC）的总裁和董事会成员。Lazar先生于2018年3月至2022年4月担任Activist Investing的首席执行官。
- David Lazar has served as a member of KALA BIO, Inc. board of directors and Chief Executive Officer since November 2025. He served as Chief Executive Officer of Novabay Pharmaceuticals, Inc. (NASDAQ: NBY) from Augt November 2025, a public biopharmaceutical company previoly foced on the development and sale of eyecare, wound care, and skin care products, from Augt 2025 to October 2025. Prior to that, Mr. Lazar previoly served as director on the board of directors of FiEE, Inc. (formerly Minim, Inc.) (NASDAQ: FIEE) where he also previoly served as the Chief Executive Officer and Chief Financial Officer from December 2023 to February 2025. Mr. Lazar served as interim Chief Executive Officer and principal financial officer of Bio Green Med Solution Inc. (NASDAQ: BGMS), from January 2, 2025 through February 26, 2025. Mr. Lazar served as the Chief Executive Officer of Black Titan Corporation listed on Nasdaq (NASDAQ: BTTC) from Augt 2022 to April 2024, where he also served as a director and board chairman from Augt 2022 until October 2023. Mr. Lazar also served as the chief executive officer and chairman of the board of directors of OpGen, Inc. (OTC: OPGN) from March 2024 to Augt 2024. Mr. Lazar also served as the president and a member of the board of directors of LQR Hoe Inc. (NASDAQ: YHC) from October 2024 to April 2025. Mr. Lazar served as the Chief Executive Officer of Activist Investing from March 2018 to April 2022.
- Todd Bazemore
-
2020年10月，Todd Bazemore被任命为Pulmatrix, Inc.公司董事。Todd Bazemore自2021年12月起担任Kala制药公司总裁兼首席运营官，并于2017年11月至2021年11月担任首席运营官。此前，他曾于2016年9月至2017年11月担任Santhera Pharmaceuticals（USA）Inc.执行副总裁兼首席运营官，该公司是一家制药公司，是Santhera Pharmaceuticals Holdings AG的子公司。在加入Santhera之前，Bazemore先生曾在2014年4月至2016年1月期间担任Dyax Corp.的执行副总裁兼首席商务官，该公司是一家专注于孤儿疾病的生物制药公司，德纳维制药被Shire plc收购。2012年4月至2013年9月期间，他在Sunovion Pharmaceuticals，Inc.，或Sunovion（大日本住友制药有限公司的子公司）担任管理市场副总裁，这是一家专注于严重疾病的全球性生物制药公司。在此之前，Bazemore先生在Sunovion担任过几个职责日益增加的职位，包括销售副总裁和呼吸业务部门副总裁。他在马萨诸塞大学洛厄尔分校获得理学学士学位。
Todd Bazemore has served as a member of KALA BIO, Inc. board of directors since 2025. Previoly, he served as Executive Vice President and Chief Operating Officer of Santhera Pharmaceuticals (A) Inc., or Santhera, a pharmaceutical company and subsidiary of Santhera Pharmaceuticals Holdings AG, from September 2016 until November 2017. Prior to joining Santhera, Mr. Bazemore served as Executive Vice President and Chief Commercial Officer of Dyax Corp., or Dyax, a biopharmaceutical company foced on orphan diseases, beten April 2014 and January 2016, when Dyax was acquired by Shire plc. At Dyax, Mr. Bazemore oversaw all aspects of Dyax's commercial department including sales, marketing, commercial analytics, market access and patient services. Beten April 2012 and September 2013, he served as Vice President, Managed Markets at Sunovion Pharmaceuticals, Inc., or Sunovion (a subsidiary of Dainippon Sumitomo Pharma Co. Ltd.), a global biopharmaceutical company foced on serio medical conditions. Prior to that, Mr. Bazemore held several roles of increasing responsibility at Sunovion, including Vice President of Sales and Vice President of Respiratory Biness Unit. Since October 2020, Mr. Bazemore has served on the board of directors of Pulmatrix Inc., a clinical stage publicly traded biopharmaceutical company. He received his Bachelor of Science from the University of Massachetts, Loll. - 2020年10月，Todd Bazemore被任命为Pulmatrix, Inc.公司董事。Todd Bazemore自2021年12月起担任Kala制药公司总裁兼首席运营官，并于2017年11月至2021年11月担任首席运营官。此前，他曾于2016年9月至2017年11月担任Santhera Pharmaceuticals（USA）Inc.执行副总裁兼首席运营官，该公司是一家制药公司，是Santhera Pharmaceuticals Holdings AG的子公司。在加入Santhera之前，Bazemore先生曾在2014年4月至2016年1月期间担任Dyax Corp.的执行副总裁兼首席商务官，该公司是一家专注于孤儿疾病的生物制药公司，德纳维制药被Shire plc收购。2012年4月至2013年9月期间，他在Sunovion Pharmaceuticals，Inc.，或Sunovion（大日本住友制药有限公司的子公司）担任管理市场副总裁，这是一家专注于严重疾病的全球性生物制药公司。在此之前，Bazemore先生在Sunovion担任过几个职责日益增加的职位，包括销售副总裁和呼吸业务部门副总裁。他在马萨诸塞大学洛厄尔分校获得理学学士学位。
- Todd Bazemore has served as a member of KALA BIO, Inc. board of directors since 2025. Previoly, he served as Executive Vice President and Chief Operating Officer of Santhera Pharmaceuticals (A) Inc., or Santhera, a pharmaceutical company and subsidiary of Santhera Pharmaceuticals Holdings AG, from September 2016 until November 2017. Prior to joining Santhera, Mr. Bazemore served as Executive Vice President and Chief Commercial Officer of Dyax Corp., or Dyax, a biopharmaceutical company foced on orphan diseases, beten April 2014 and January 2016, when Dyax was acquired by Shire plc. At Dyax, Mr. Bazemore oversaw all aspects of Dyax's commercial department including sales, marketing, commercial analytics, market access and patient services. Beten April 2012 and September 2013, he served as Vice President, Managed Markets at Sunovion Pharmaceuticals, Inc., or Sunovion (a subsidiary of Dainippon Sumitomo Pharma Co. Ltd.), a global biopharmaceutical company foced on serio medical conditions. Prior to that, Mr. Bazemore held several roles of increasing responsibility at Sunovion, including Vice President of Sales and Vice President of Respiratory Biness Unit. Since October 2020, Mr. Bazemore has served on the board of directors of Pulmatrix Inc., a clinical stage publicly traded biopharmaceutical company. He received his Bachelor of Science from the University of Massachetts, Loll.
- Avi Minkowitz
-
Avi Minkowitz在被任命为公司首席执行官兼首席财务官之前，Minkowitz先生于2018年7月至2020年12月期间担任Parkit Enterprise Inc.（TSX：PKT.V）的副总裁，该公司现为一家工业房地产平台。以这种身份，他为公司担保并承销了潜在的房地产收购交易。他的任期以成功承销并与一家业内房地产实体合并而告终。随后，他于2021年1月至2024年10月在家族办公室投资公司Leonite Capital担任分析师，主要专注于上市公司融资、并购和BINCE Development。此外，自2023年以来，他还担任管理顾问，为公司提供增长、重组和融资方面的建议。Minkowitz目前于2025年11月开始担任NuRAN Wireless Inc.（CSE：NUR）的董事会成员，2022年10月开始担任International Star Inc.（OTC：ILST）的董事会成员。他同时拥有加拿大多伦多约克大学心理学专业荣誉学士学位和灾害与应急管理硕士学位。
Avi Minkowitz Prior to his appointment as the Company's Chief Executive Officer and Chief Financial Officer, Mr. Minkowitz served as Vice President at Parkit Enterprise Inc. (TSX: PKT.V), now an indtrial real estate platform, from July 2018 to December 2020. In that capacity, he sced and underwrote potential real estate acquisitions for the Company. His tenure ended with the successful underwriting and merger with an indtrial real estate entity. He subsequently served as an Analyst at Leonite Capital, a family office investment firm, from January 2021 to October 2024, where he foced primarily on financing for publicly traded companies, M&A, and biness development. In addition, since 2023, he has worked as a Management Consultant, advising companies on growth, restructuring, and financing.Mr. Minkowitz currently serves on the board of directors at NuRAN Wireless Inc. (CSE: NUR) beginning in November 2025, and of International Star Inc. (OTC: ILST) beginning in October 2022.He holds both a specialized hons bachelor's degree in psychology and a master's degree in disaster and emergency management from York University in Toronto, Canada. - Avi Minkowitz在被任命为公司首席执行官兼首席财务官之前，Minkowitz先生于2018年7月至2020年12月期间担任Parkit Enterprise Inc.（TSX：PKT.V）的副总裁，该公司现为一家工业房地产平台。以这种身份，他为公司担保并承销了潜在的房地产收购交易。他的任期以成功承销并与一家业内房地产实体合并而告终。随后，他于2021年1月至2024年10月在家族办公室投资公司Leonite Capital担任分析师，主要专注于上市公司融资、并购和BINCE Development。此外，自2023年以来，他还担任管理顾问，为公司提供增长、重组和融资方面的建议。Minkowitz目前于2025年11月开始担任NuRAN Wireless Inc.（CSE：NUR）的董事会成员，2022年10月开始担任International Star Inc.（OTC：ILST）的董事会成员。他同时拥有加拿大多伦多约克大学心理学专业荣誉学士学位和灾害与应急管理硕士学位。
- Avi Minkowitz Prior to his appointment as the Company's Chief Executive Officer and Chief Financial Officer, Mr. Minkowitz served as Vice President at Parkit Enterprise Inc. (TSX: PKT.V), now an indtrial real estate platform, from July 2018 to December 2020. In that capacity, he sced and underwrote potential real estate acquisitions for the Company. His tenure ended with the successful underwriting and merger with an indtrial real estate entity. He subsequently served as an Analyst at Leonite Capital, a family office investment firm, from January 2021 to October 2024, where he foced primarily on financing for publicly traded companies, M&A, and biness development. In addition, since 2023, he has worked as a Management Consultant, advising companies on growth, restructuring, and financing.Mr. Minkowitz currently serves on the board of directors at NuRAN Wireless Inc. (CSE: NUR) beginning in November 2025, and of International Star Inc. (OTC: ILST) beginning in October 2022.He holds both a specialized hons bachelor's degree in psychology and a master's degree in disaster and emergency management from York University in Toronto, Canada.
- Andrew I. Koven
-
Andrew I. Koven，是NeuroBo Pharmaceuticals, Inc.董事会成员。他是Kala Pharmaceuticals, Inc.（一家上市生物制药公司，专注于眼病创新疗法的发现、开发和商业化）的首席独立董事。他曾担任Kala Pharmaceuticals, Inc.的首席独立董事（2018年12月以来），以及Kala董事会成员（2017年9月以来）。他曾担任Aralez Pharmaceuticals Inc.（公共专业制药公司）的首席商务官（直到2019年1月退休），以及Aralez Pharmaceuticals Inc.的前身Pozen Inc.的首席商务官（从2015年6月开始）。加入Pozen之前，他曾担任Auxilium Pharmaceuticals Inc.（公共专业生物制药公司）的执行副总裁、首席行政官和总法律顾问（从2012年2月到2015年1月），当时该公司被Endo International plc收购。2011年9月至2011年11月，他担任Neurologix, Inc.（专注于多种创新基因治疗开发项目的开发）的总裁、首席行政官和董事会成员。在Neurologix之前，他曾担任Inspire Pharmaceuticals, Inc.的执行副总裁、首席行政和法律官（从2010年7月到2011年5月该公司被Merck & Co.收购）。此前，他曾担任Sepracor Inc.（现为Sunovion）的执行副总裁、总法律顾问和公司秘书（从2007年3月到2010年2月被Dainippon Sumitomo Pharma Co.， Ltd.收购）。加入Sepracor之前，从2003年8月到2006年12月被Abbott Laboratories（现AbbVie）收购，他担任Kos Pharmaceuticals, Inc.（一家公共专业制药公司）的执行副总裁、总法律顾问和公司秘书。他的职业生涯始于制药行业，从1993年到2000年担任Warner-Lambert Company的助理总法律顾问，然后是助理总法律顾问，从2000年到2003年担任lavpharm Corporation的高级副总裁和总法律顾问。从1986年到1992年，他是纽约Cahill, Gordon & Reindel公司的合伙人。从1992年到1993年，他担任The Equitable Life Assurance Society of The u.s。的公司和投资部门的法律顾问。他持有哥伦比亚大学法学院法学硕士学位和Dalhousie大学政治学学士学位和法学学士学位。
Andrew I. Koven has served as a member of KALA BIO, Inc. board of directors since September 2017 and as KALA BIO, Inc. Lead Independent Director since December 2018. Mr. Koven was, until his retirement in January 2019, the President and Chief Biness Officer of Aralez Pharmaceuticals Inc., or Aralez, a public specialty pharmaceutical company, and served in that role with the company's predecessor, Pozen Inc., or Pozen, commencing in June 2015. Prior to joining Pozen, Mr. Koven served as Executive Vice President, Chief Administrative Officer and General Counsel of Auxilium Pharmaceuticals Inc., a public specialty biopharmaceutical company, from February 2012 until January 2015, when it was acquired by Endo International plc. Mr. Koven served as President and Chief Administrative Officer and a member of the board of directors of Neurologix, Inc., a company foced on the development of multiple innovative gene therapy development programs, from September 2011 to November 2011. Before Neurologix, Mr. Koven served as Executive Vice President and Chief Administrative and Legal Officer of Inspire Pharmaceuticals, Inc., a public specialty pharmaceutical company, from July 2010 until May 2011 when it was acquired by Merck & Co., Inc. Previoly, Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary of Sepracor Inc. (now Sunovion Pharmaceuticals, Inc., or Sunovion), a public specialty pharmaceutical company, from March 2007 until February 2010 when it was acquired by Dainippon Sumitomo Pharma Co., Ltd. Prior to joining Sepracor Inc., Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary of Kos Pharmaceuticals, Inc., a public specialty pharmaceutical company, from Augt 2003 until its acquisition by Abbott Laboratories (now AbbVie) in December 2006. Mr. Koven began his career in the pharmaceutical indtry first as an Assistant General Counsel and then as Associate General Counsel at Warner Lambert Company from 1993 to 2000, follod by his role as Senior Vice President and General Counsel at Lavipharm Corporation from 2000 to 2003. Mr. Koven also currently serves on the board of NeuroBo Pharmaceuticals, Inc., or NeuroBo, a publicly traded company, and has served as its Chair since January 2022. Mr. Koven is also a member of NeuroBo's Audit Committee and Chair of its Nominating and Corporate Governance Committee. From 1986 to 1992 he was a corporate associate at Cahill, Gordon & Reindel in New York. From 1992 to 1993 he served as Counsel, Corporate and Investment Division, at The Equitable Life Assurance Society of the U.S. Mr. Koven holds a Master of Laws (LL.M.) Degree from Columbia University School of Law and a Bachelor of Laws (LL.B.) Degree and Bachelor of Arts Degree in Political Science from Dalhoie University. - Andrew I. Koven，是NeuroBo Pharmaceuticals, Inc.董事会成员。他是Kala Pharmaceuticals, Inc.（一家上市生物制药公司，专注于眼病创新疗法的发现、开发和商业化）的首席独立董事。他曾担任Kala Pharmaceuticals, Inc.的首席独立董事（2018年12月以来），以及Kala董事会成员（2017年9月以来）。他曾担任Aralez Pharmaceuticals Inc.（公共专业制药公司）的首席商务官（直到2019年1月退休），以及Aralez Pharmaceuticals Inc.的前身Pozen Inc.的首席商务官（从2015年6月开始）。加入Pozen之前，他曾担任Auxilium Pharmaceuticals Inc.（公共专业生物制药公司）的执行副总裁、首席行政官和总法律顾问（从2012年2月到2015年1月），当时该公司被Endo International plc收购。2011年9月至2011年11月，他担任Neurologix, Inc.（专注于多种创新基因治疗开发项目的开发）的总裁、首席行政官和董事会成员。在Neurologix之前，他曾担任Inspire Pharmaceuticals, Inc.的执行副总裁、首席行政和法律官（从2010年7月到2011年5月该公司被Merck & Co.收购）。此前，他曾担任Sepracor Inc.（现为Sunovion）的执行副总裁、总法律顾问和公司秘书（从2007年3月到2010年2月被Dainippon Sumitomo Pharma Co.， Ltd.收购）。加入Sepracor之前，从2003年8月到2006年12月被Abbott Laboratories（现AbbVie）收购，他担任Kos Pharmaceuticals, Inc.（一家公共专业制药公司）的执行副总裁、总法律顾问和公司秘书。他的职业生涯始于制药行业，从1993年到2000年担任Warner-Lambert Company的助理总法律顾问，然后是助理总法律顾问，从2000年到2003年担任lavpharm Corporation的高级副总裁和总法律顾问。从1986年到1992年，他是纽约Cahill, Gordon & Reindel公司的合伙人。从1992年到1993年，他担任The Equitable Life Assurance Society of The u.s。的公司和投资部门的法律顾问。他持有哥伦比亚大学法学院法学硕士学位和Dalhousie大学政治学学士学位和法学学士学位。
- Andrew I. Koven has served as a member of KALA BIO, Inc. board of directors since September 2017 and as KALA BIO, Inc. Lead Independent Director since December 2018. Mr. Koven was, until his retirement in January 2019, the President and Chief Biness Officer of Aralez Pharmaceuticals Inc., or Aralez, a public specialty pharmaceutical company, and served in that role with the company's predecessor, Pozen Inc., or Pozen, commencing in June 2015. Prior to joining Pozen, Mr. Koven served as Executive Vice President, Chief Administrative Officer and General Counsel of Auxilium Pharmaceuticals Inc., a public specialty biopharmaceutical company, from February 2012 until January 2015, when it was acquired by Endo International plc. Mr. Koven served as President and Chief Administrative Officer and a member of the board of directors of Neurologix, Inc., a company foced on the development of multiple innovative gene therapy development programs, from September 2011 to November 2011. Before Neurologix, Mr. Koven served as Executive Vice President and Chief Administrative and Legal Officer of Inspire Pharmaceuticals, Inc., a public specialty pharmaceutical company, from July 2010 until May 2011 when it was acquired by Merck & Co., Inc. Previoly, Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary of Sepracor Inc. (now Sunovion Pharmaceuticals, Inc., or Sunovion), a public specialty pharmaceutical company, from March 2007 until February 2010 when it was acquired by Dainippon Sumitomo Pharma Co., Ltd. Prior to joining Sepracor Inc., Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary of Kos Pharmaceuticals, Inc., a public specialty pharmaceutical company, from Augt 2003 until its acquisition by Abbott Laboratories (now AbbVie) in December 2006. Mr. Koven began his career in the pharmaceutical indtry first as an Assistant General Counsel and then as Associate General Counsel at Warner Lambert Company from 1993 to 2000, follod by his role as Senior Vice President and General Counsel at Lavipharm Corporation from 2000 to 2003. Mr. Koven also currently serves on the board of NeuroBo Pharmaceuticals, Inc., or NeuroBo, a publicly traded company, and has served as its Chair since January 2022. Mr. Koven is also a member of NeuroBo's Audit Committee and Chair of its Nominating and Corporate Governance Committee. From 1986 to 1992 he was a corporate associate at Cahill, Gordon & Reindel in New York. From 1992 to 1993 he served as Counsel, Corporate and Investment Division, at The Equitable Life Assurance Society of the U.S. Mr. Koven holds a Master of Laws (LL.M.) Degree from Columbia University School of Law and a Bachelor of Laws (LL.B.) Degree and Bachelor of Arts Degree in Political Science from Dalhoie University.
- C. Daniel Myers
-
C. Daniel Myers，他是公司的共同创办人之一，公司于2003年成立以来他一直担任公司行政总裁及董事。在创办公司前，他为诺华眼药公司和视康公司的第一批员工眼药，并从1991年至1997年担任销售和营销的副总裁，从1997至2003年担任总裁。他持有佐治亚理工学院工业管理学士学位。
C. Daniel Myers has served as a member of KALA BIO, Inc. board of directors since October 2021. Mr. Myers served as the Chief Executive Officer of MediPrint Ophthalmics, Inc. (formerly Leo Lens Pharma), a private eye care company, from April 2020 to April 2022. Previoly, Mr. Myers co founded Alimera Sciences, Inc., or Alimera, a publicly traded pharmaceutical company, and served as its Chief Executive Officer from 2003 until January 2019. Before co founding Alimera, Mr. Myers was an initial employee of Novartis Ophthalmics (formerly CIBA Vision Ophthalmics), a pharmaceutical company, and served as its Vice President of sales and marketing from 1991 to 1997 and as President from 1997 to 2003. Mr. Myers served as a director of Alimera from 2003 to Augt 2023, and as chairman of its board of directors from January 2019 to Augt 2023. Mr. Myers currently serves as Chairman Emerit of Alimera. In addition, Mr. Myers served on the board of directors of Ocular Therapeutix, Inc., a publicly traded biopharmaceutical company, from 2009 to 2012. Mr. Myers holds a B.S. in Indtrial Management from the Georgia Institute of Technology. - C. Daniel Myers，他是公司的共同创办人之一，公司于2003年成立以来他一直担任公司行政总裁及董事。在创办公司前，他为诺华眼药公司和视康公司的第一批员工眼药，并从1991年至1997年担任销售和营销的副总裁，从1997至2003年担任总裁。他持有佐治亚理工学院工业管理学士学位。
- C. Daniel Myers has served as a member of KALA BIO, Inc. board of directors since October 2021. Mr. Myers served as the Chief Executive Officer of MediPrint Ophthalmics, Inc. (formerly Leo Lens Pharma), a private eye care company, from April 2020 to April 2022. Previoly, Mr. Myers co founded Alimera Sciences, Inc., or Alimera, a publicly traded pharmaceutical company, and served as its Chief Executive Officer from 2003 until January 2019. Before co founding Alimera, Mr. Myers was an initial employee of Novartis Ophthalmics (formerly CIBA Vision Ophthalmics), a pharmaceutical company, and served as its Vice President of sales and marketing from 1991 to 1997 and as President from 1997 to 2003. Mr. Myers served as a director of Alimera from 2003 to Augt 2023, and as chairman of its board of directors from January 2019 to Augt 2023. Mr. Myers currently serves as Chairman Emerit of Alimera. In addition, Mr. Myers served on the board of directors of Ocular Therapeutix, Inc., a publicly traded biopharmaceutical company, from 2009 to 2012. Mr. Myers holds a B.S. in Indtrial Management from the Georgia Institute of Technology.
高管简历
中英对照 | 中文 | 英文- Kim Brazzell
Kim Brazzell自2013年2月以来一直担任我们的首席医疗官。他也曾担任Acuity Advisors公司（眼科咨询公司）的负责人（2014年1月以来）。Brazzell从2012年1月到2015年12月担任Mimetogen Pharmaceuticals，Inc.（一家临床阶段生物技术公司）首席医疗官。Brazzell博士还在InspirePharmaceuticals，Inc.公司（Inspire）担任过多个高管职位，该公司是一家专注于眼科产品的专业制药公司，包括2010年至2011年担任医疗和科学事务执行Vice President，2009年至2010年担任执行Vice President和眼科业务主管，2004年至2008年担任眼科研究与开发高级副总裁。在加入Inspire之前，Brazzell博士从2000年到2004年担任Novartis Ophthalmics AG临床研发和高级副总裁，美国研发的全球主管。Brazzell博士还担任Ciba Vision Ophthalmics，Inc.的研发Vice President和Alcon Laboratories，Inc.的研发副总监。Brazzell博士在肯塔基大学（University of Kentucky）获得药学学士学位和制药科学博士学位。
Kim Brazzell has served as KALA BIO, Inc. Chief Medical Officer since February 2013 and as KALA BIO, Inc. Head of Research and Development since December 2021. Dr. Brazzell served as Chief Medical Officer of Mimetogen Pharmaceuticals, Inc., or Mimetogen, a clinical stage biotechnology company, from January 2012 until December 2015 and has served on the board of directors of Mimetogen since January 2024. Dr. Brazzell also held several executive positions at Inspire Pharmaceuticals, Inc., or Inspire, a specialty pharmaceutical company focing on ophthalmic and respiratory products, including Executive Vice President of Medical and Scientific Affairs from 2010 to 2011, Executive Vice President and Head of Ophthalology Biness from 2009 to 2010, and Senior Vice President of Ophthalmic Research and Development from 2004 to 2008. Prior to joining Inspire, Dr. Brazzell served as Global Head of Clinical R&D and Senior Vice President, U.S. R&D, of Novartis Ophthalmics AG from 2000 to 2004. Dr. Brazzell also served as Vice President, R&D at Ciba Vision Ophthalmics, Inc. and as Associate Director, R&D, at Alcon Laboratories, Inc. Dr. Brazzell received a B.S. in Pharmacy and a Ph.D. in Pharmaceutical Sciences from the University of Kentucky.- Kim Brazzell自2013年2月以来一直担任我们的首席医疗官。他也曾担任Acuity Advisors公司（眼科咨询公司）的负责人（2014年1月以来）。Brazzell从2012年1月到2015年12月担任Mimetogen Pharmaceuticals，Inc.（一家临床阶段生物技术公司）首席医疗官。Brazzell博士还在InspirePharmaceuticals，Inc.公司（Inspire）担任过多个高管职位，该公司是一家专注于眼科产品的专业制药公司，包括2010年至2011年担任医疗和科学事务执行Vice President，2009年至2010年担任执行Vice President和眼科业务主管，2004年至2008年担任眼科研究与开发高级副总裁。在加入Inspire之前，Brazzell博士从2000年到2004年担任Novartis Ophthalmics AG临床研发和高级副总裁，美国研发的全球主管。Brazzell博士还担任Ciba Vision Ophthalmics，Inc.的研发Vice President和Alcon Laboratories，Inc.的研发副总监。Brazzell博士在肯塔基大学（University of Kentucky）获得药学学士学位和制药科学博士学位。
- Kim Brazzell has served as KALA BIO, Inc. Chief Medical Officer since February 2013 and as KALA BIO, Inc. Head of Research and Development since December 2021. Dr. Brazzell served as Chief Medical Officer of Mimetogen Pharmaceuticals, Inc., or Mimetogen, a clinical stage biotechnology company, from January 2012 until December 2015 and has served on the board of directors of Mimetogen since January 2024. Dr. Brazzell also held several executive positions at Inspire Pharmaceuticals, Inc., or Inspire, a specialty pharmaceutical company focing on ophthalmic and respiratory products, including Executive Vice President of Medical and Scientific Affairs from 2010 to 2011, Executive Vice President and Head of Ophthalology Biness from 2009 to 2010, and Senior Vice President of Ophthalmic Research and Development from 2004 to 2008. Prior to joining Inspire, Dr. Brazzell served as Global Head of Clinical R&D and Senior Vice President, U.S. R&D, of Novartis Ophthalmics AG from 2000 to 2004. Dr. Brazzell also served as Vice President, R&D at Ciba Vision Ophthalmics, Inc. and as Associate Director, R&D, at Alcon Laboratories, Inc. Dr. Brazzell received a B.S. in Pharmacy and a Ph.D. in Pharmaceutical Sciences from the University of Kentucky.
- David Lazar
David Lazar自2025年11月起担任KALA BIO，Inc.董事会成员兼首席执行官。他于2025年8月至2025年10月担任Novabay Pharmaceuticals, Inc.（NASDAQ：NBY）的首席执行官，该公司是一家上市生物制药公司previoly，专注于开发和销售眼部护理、伤口护理和皮肤护理产品。在此之前，Lazar Previoly先生在FiEE，Inc.（前身为Minim, Inc.）（纳斯达克股票代码：FIEE）的董事会担任董事，他还在2023年12月至2025年2月期间担任首席执行官和首席财务官。Lazar先生于2025年1月2日至2025年2月26日期间担任Bio Green Med Solution Inc.（纳斯达克股票代码：BGMS）的临时首席执行官和首席财务官。Lazar先生于2022年8月至2024年4月期间担任在纳斯达克上市的Black Titan Corporation（NASDAQ：BTTC）的首席执行官，并于2022年8月至2023年10月期间担任董事和董事会主席。Lazar先生还于2024年3月至2024年8月期间担任OpGen公司（OTC：OPGN）的首席执行官兼董事会主席。Lazar先生还曾在2024年10月至2025年4月期间担任LQR Hoe Inc.（纳斯达克股票代码：YHC）的总裁和董事会成员。Lazar先生于2018年3月至2022年4月担任Activist Investing的首席执行官。
David Lazar has served as a member of KALA BIO, Inc. board of directors and Chief Executive Officer since November 2025. He served as Chief Executive Officer of Novabay Pharmaceuticals, Inc. (NASDAQ: NBY) from Augt November 2025, a public biopharmaceutical company previoly foced on the development and sale of eyecare, wound care, and skin care products, from Augt 2025 to October 2025. Prior to that, Mr. Lazar previoly served as director on the board of directors of FiEE, Inc. (formerly Minim, Inc.) (NASDAQ: FIEE) where he also previoly served as the Chief Executive Officer and Chief Financial Officer from December 2023 to February 2025. Mr. Lazar served as interim Chief Executive Officer and principal financial officer of Bio Green Med Solution Inc. (NASDAQ: BGMS), from January 2, 2025 through February 26, 2025. Mr. Lazar served as the Chief Executive Officer of Black Titan Corporation listed on Nasdaq (NASDAQ: BTTC) from Augt 2022 to April 2024, where he also served as a director and board chairman from Augt 2022 until October 2023. Mr. Lazar also served as the chief executive officer and chairman of the board of directors of OpGen, Inc. (OTC: OPGN) from March 2024 to Augt 2024. Mr. Lazar also served as the president and a member of the board of directors of LQR Hoe Inc. (NASDAQ: YHC) from October 2024 to April 2025. Mr. Lazar served as the Chief Executive Officer of Activist Investing from March 2018 to April 2022.- David Lazar自2025年11月起担任KALA BIO，Inc.董事会成员兼首席执行官。他于2025年8月至2025年10月担任Novabay Pharmaceuticals, Inc.（NASDAQ：NBY）的首席执行官，该公司是一家上市生物制药公司previoly，专注于开发和销售眼部护理、伤口护理和皮肤护理产品。在此之前，Lazar Previoly先生在FiEE，Inc.（前身为Minim, Inc.）（纳斯达克股票代码：FIEE）的董事会担任董事，他还在2023年12月至2025年2月期间担任首席执行官和首席财务官。Lazar先生于2025年1月2日至2025年2月26日期间担任Bio Green Med Solution Inc.（纳斯达克股票代码：BGMS）的临时首席执行官和首席财务官。Lazar先生于2022年8月至2024年4月期间担任在纳斯达克上市的Black Titan Corporation（NASDAQ：BTTC）的首席执行官，并于2022年8月至2023年10月期间担任董事和董事会主席。Lazar先生还于2024年3月至2024年8月期间担任OpGen公司（OTC：OPGN）的首席执行官兼董事会主席。Lazar先生还曾在2024年10月至2025年4月期间担任LQR Hoe Inc.（纳斯达克股票代码：YHC）的总裁和董事会成员。Lazar先生于2018年3月至2022年4月担任Activist Investing的首席执行官。
- David Lazar has served as a member of KALA BIO, Inc. board of directors and Chief Executive Officer since November 2025. He served as Chief Executive Officer of Novabay Pharmaceuticals, Inc. (NASDAQ: NBY) from Augt November 2025, a public biopharmaceutical company previoly foced on the development and sale of eyecare, wound care, and skin care products, from Augt 2025 to October 2025. Prior to that, Mr. Lazar previoly served as director on the board of directors of FiEE, Inc. (formerly Minim, Inc.) (NASDAQ: FIEE) where he also previoly served as the Chief Executive Officer and Chief Financial Officer from December 2023 to February 2025. Mr. Lazar served as interim Chief Executive Officer and principal financial officer of Bio Green Med Solution Inc. (NASDAQ: BGMS), from January 2, 2025 through February 26, 2025. Mr. Lazar served as the Chief Executive Officer of Black Titan Corporation listed on Nasdaq (NASDAQ: BTTC) from Augt 2022 to April 2024, where he also served as a director and board chairman from Augt 2022 until October 2023. Mr. Lazar also served as the chief executive officer and chairman of the board of directors of OpGen, Inc. (OTC: OPGN) from March 2024 to Augt 2024. Mr. Lazar also served as the president and a member of the board of directors of LQR Hoe Inc. (NASDAQ: YHC) from October 2024 to April 2025. Mr. Lazar served as the Chief Executive Officer of Activist Investing from March 2018 to April 2022.
- Darius Kharabi
Darius Kharabi，自2021年11月起担任Kala制药有限公司首席商务官。从2018年8月到2021年11月，Kharabi先生是Combangio Inc.的联合创始人兼首席执行官，这是一家临床阶段的眼科间充质干细胞分泌组公司，我们于2021年11月收购了该公司。他是早期医疗投资公司Lagunita Biosciences，LLC的联合创始人。自2015年以来，Kharabi先生一直担任Lagunita Biosciences，LLC的首席运营官。从2015年10月到2018年8月，他帮助创建和管理了多家Lagunita生命科学公司，包括被Ligand收购的xCella Biosciences、被诺华收购的Kedalion Therapeutics和Combangio。2015年10月至2019年8月，他担任xCella Biosciences首席运营官，2015年10月至2017年11月，他担任Kedalion总裁。在加入Lagunita之前，他曾在OrthAlign担任企业发展和国际销售副总裁，该公司是一家处于商业阶段的骨科手术导航公司，负责在美国和全球市场推出KneeAlign 全膝关节置换术导航产品线。哈拉比的职业生涯始于Wilson，Sonsini，Goodrich & Rosati，PC的生物技术许可律师。他在乔治城大学获得生物化学学士学位，在斯坦福大学获得法学博士和工商管理硕士学位。
Darius Kharabi has served as KALA BIO, Inc. Chief Biness Officer since November 2021. From Augt 2018 to November 2021, Mr. Kharabi was co founder and Chief Executive Officer of Combangio Inc., a clinical stage ophthalmology mesenchymal stem cell secretome company that acquired in November 2021. He is the co founder of Lagunita Biosciences, LLC, an early stage medical investment company. Since 2015, Mr. Kharabi has served as the Chief Operating Officer of Lagunita Biosciences, LLC. From October 2015 to Augt 2018 he helped create and manage multiple Lagunita portfolio life science companies, including xCella Biosciences, acquired by Ligand, Kedalion Therapeutics, acquired by Novartis AG, and Combangio. From October 2015 through Augt 2019 he served as the Chief Operating Officer of xCella Biosciences and from October 2015 through November 2017 he served as the President of Kedalion. Prior to Lagunita, he served as Vice President, Corporate Development and International Sales at OrthAlign, a commercial stage orthopedic surgery navigation company, where his responsibilities included the launch of the KneeAlign total knee arthroplasty navigation product line in the United States and global markets. Mr. Kharabi started his career as a biotechnology licensing attorney at Wilson, Sonsini, Goodrich & Rosati, PC. He received his B.S. in Biochemistry from Georgetown University and his J.D. and M.B.A. degrees from Stanford University.- Darius Kharabi，自2021年11月起担任Kala制药有限公司首席商务官。从2018年8月到2021年11月，Kharabi先生是Combangio Inc.的联合创始人兼首席执行官，这是一家临床阶段的眼科间充质干细胞分泌组公司，我们于2021年11月收购了该公司。他是早期医疗投资公司Lagunita Biosciences，LLC的联合创始人。自2015年以来，Kharabi先生一直担任Lagunita Biosciences，LLC的首席运营官。从2015年10月到2018年8月，他帮助创建和管理了多家Lagunita生命科学公司，包括被Ligand收购的xCella Biosciences、被诺华收购的Kedalion Therapeutics和Combangio。2015年10月至2019年8月，他担任xCella Biosciences首席运营官，2015年10月至2017年11月，他担任Kedalion总裁。在加入Lagunita之前，他曾在OrthAlign担任企业发展和国际销售副总裁，该公司是一家处于商业阶段的骨科手术导航公司，负责在美国和全球市场推出KneeAlign 全膝关节置换术导航产品线。哈拉比的职业生涯始于Wilson，Sonsini，Goodrich & Rosati，PC的生物技术许可律师。他在乔治城大学获得生物化学学士学位，在斯坦福大学获得法学博士和工商管理硕士学位。
- Darius Kharabi has served as KALA BIO, Inc. Chief Biness Officer since November 2021. From Augt 2018 to November 2021, Mr. Kharabi was co founder and Chief Executive Officer of Combangio Inc., a clinical stage ophthalmology mesenchymal stem cell secretome company that acquired in November 2021. He is the co founder of Lagunita Biosciences, LLC, an early stage medical investment company. Since 2015, Mr. Kharabi has served as the Chief Operating Officer of Lagunita Biosciences, LLC. From October 2015 to Augt 2018 he helped create and manage multiple Lagunita portfolio life science companies, including xCella Biosciences, acquired by Ligand, Kedalion Therapeutics, acquired by Novartis AG, and Combangio. From October 2015 through Augt 2019 he served as the Chief Operating Officer of xCella Biosciences and from October 2015 through November 2017 he served as the President of Kedalion. Prior to Lagunita, he served as Vice President, Corporate Development and International Sales at OrthAlign, a commercial stage orthopedic surgery navigation company, where his responsibilities included the launch of the KneeAlign total knee arthroplasty navigation product line in the United States and global markets. Mr. Kharabi started his career as a biotechnology licensing attorney at Wilson, Sonsini, Goodrich & Rosati, PC. He received his B.S. in Biochemistry from Georgetown University and his J.D. and M.B.A. degrees from Stanford University.
- Avi Minkowitz
Avi Minkowitz在被任命为公司首席执行官兼首席财务官之前，Minkowitz先生于2018年7月至2020年12月期间担任Parkit Enterprise Inc.（TSX：PKT.V）的副总裁，该公司现为一家工业房地产平台。以这种身份，他为公司担保并承销了潜在的房地产收购交易。他的任期以成功承销并与一家业内房地产实体合并而告终。随后，他于2021年1月至2024年10月在家族办公室投资公司Leonite Capital担任分析师，主要专注于上市公司融资、并购和BINCE Development。此外，自2023年以来，他还担任管理顾问，为公司提供增长、重组和融资方面的建议。Minkowitz目前于2025年11月开始担任NuRAN Wireless Inc.（CSE：NUR）的董事会成员，2022年10月开始担任International Star Inc.（OTC：ILST）的董事会成员。他同时拥有加拿大多伦多约克大学心理学专业荣誉学士学位和灾害与应急管理硕士学位。
Avi Minkowitz Prior to his appointment as the Company's Chief Executive Officer and Chief Financial Officer, Mr. Minkowitz served as Vice President at Parkit Enterprise Inc. (TSX: PKT.V), now an indtrial real estate platform, from July 2018 to December 2020. In that capacity, he sced and underwrote potential real estate acquisitions for the Company. His tenure ended with the successful underwriting and merger with an indtrial real estate entity. He subsequently served as an Analyst at Leonite Capital, a family office investment firm, from January 2021 to October 2024, where he foced primarily on financing for publicly traded companies, M&A, and biness development. In addition, since 2023, he has worked as a Management Consultant, advising companies on growth, restructuring, and financing.Mr. Minkowitz currently serves on the board of directors at NuRAN Wireless Inc. (CSE: NUR) beginning in November 2025, and of International Star Inc. (OTC: ILST) beginning in October 2022.He holds both a specialized hons bachelor's degree in psychology and a master's degree in disaster and emergency management from York University in Toronto, Canada.- Avi Minkowitz在被任命为公司首席执行官兼首席财务官之前，Minkowitz先生于2018年7月至2020年12月期间担任Parkit Enterprise Inc.（TSX：PKT.V）的副总裁，该公司现为一家工业房地产平台。以这种身份，他为公司担保并承销了潜在的房地产收购交易。他的任期以成功承销并与一家业内房地产实体合并而告终。随后，他于2021年1月至2024年10月在家族办公室投资公司Leonite Capital担任分析师，主要专注于上市公司融资、并购和BINCE Development。此外，自2023年以来，他还担任管理顾问，为公司提供增长、重组和融资方面的建议。Minkowitz目前于2025年11月开始担任NuRAN Wireless Inc.（CSE：NUR）的董事会成员，2022年10月开始担任International Star Inc.（OTC：ILST）的董事会成员。他同时拥有加拿大多伦多约克大学心理学专业荣誉学士学位和灾害与应急管理硕士学位。
- Avi Minkowitz Prior to his appointment as the Company's Chief Executive Officer and Chief Financial Officer, Mr. Minkowitz served as Vice President at Parkit Enterprise Inc. (TSX: PKT.V), now an indtrial real estate platform, from July 2018 to December 2020. In that capacity, he sced and underwrote potential real estate acquisitions for the Company. His tenure ended with the successful underwriting and merger with an indtrial real estate entity. He subsequently served as an Analyst at Leonite Capital, a family office investment firm, from January 2021 to October 2024, where he foced primarily on financing for publicly traded companies, M&A, and biness development. In addition, since 2023, he has worked as a Management Consultant, advising companies on growth, restructuring, and financing.Mr. Minkowitz currently serves on the board of directors at NuRAN Wireless Inc. (CSE: NUR) beginning in November 2025, and of International Star Inc. (OTC: ILST) beginning in October 2022.He holds both a specialized hons bachelor's degree in psychology and a master's degree in disaster and emergency management from York University in Toronto, Canada.